June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Intravitreal long-lasting micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) for cytomegalovirus retinitis
Author Affiliations & Notes
  • Feiyan Ma
    Ophthalmology, Shiley Eye Center, UCSD, La Jolla, CA
  • Su-Na Lee
    Ophthalmology, Shiley Eye Center, UCSD, La Jolla, CA
  • Huiyuan Hou
    Ophthalmology, Shiley Eye Center, UCSD, La Jolla, CA
  • James Beadle
    Department of Medicine, San Diego VA Healthcare System and UC San Diego, LA JOLLA, CA
  • William Freeman
    Ophthalmology, Shiley Eye Center, UCSD, La Jolla, CA
  • Karl Hostetler
    Department of Medicine, San Diego VA Healthcare System and UC San Diego, LA JOLLA, CA
  • Lingyun Cheng
    Ophthalmology, Shiley Eye Center, UCSD, La Jolla, CA
  • Footnotes
    Commercial Relationships Feiyan Ma, None; Su-Na Lee, None; Huiyuan Hou, None; James Beadle, Chimerix Pharmaceuticals (I); William Freeman, OD-OS, Inc. (C); Karl Hostetler, None; Lingyun Cheng, Spinnaker Biosciences (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3208. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Feiyan Ma, Su-Na Lee, Huiyuan Hou, James Beadle, William Freeman, Karl Hostetler, Lingyun Cheng; Intravitreal long-lasting micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) for cytomegalovirus retinitis. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3208.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: We have previously shown that micelle formulation of HDP-CDV had a long vitreous half-life and good ocular safety profile. In the current study, we applied a pre-treatment strategy to evaluate the sustained therapeutic effect of hexadecyloxypropyl-cidofovir (HDP-CDV) against a rabbit HSV retinitis model.

Methods: Twenty-seven New Zealand pigmented rabbits (27 eyes) received either an intravitreal equal molar concentrations of HDP-CDV (42μg/50μl), CDV (28 μg/50μl) or 5% dextrose (50μl) as controls 5 weeks or 9 weeks before HSV intravitreal inoculation. Intravitreal injection of a 5×10-5 dilution of 108TCID/mL HSV was performed to induce HSV retinitis. After the virus injection, the rabbit eyes were monitored by indirect ophthalmoscopy and the retinitis was graded as 0.5, 1, 2, 3, and 4 as we described previously on day 3, day 6, day 9, and day 14 on which rabbits were sacrificed for pathological evaluation. The retinitis scores were compared among the HDP-CDV, free CDV, and dextrose groups.

Results: HSV retinitis in rabbits is a rapidly spreading retinitis model. It presents on day 4 to 6 after virus inoculation and shows rapid progression between day 6 and day 9 before a complete retinitis on day 14. For the 5-week pretreatment study, the retinitis scores on day 6 and day 9 were pooled and treated as a repeated measurement as ordinary scale to compare the retinitis severity among the three groups. HDP-CDV showed significantly less retinitis than dextrose controls (p=0.0047), though no significant difference from CDV group (p=0.22). For the 9-week pretreatment study, HDP-CDV group showed a significantly less retinitis than CDV group (p=0.0053) and dextrose group (p=0.0097). At week 9, CDV had same severe retinitis as the dextrose injected eyes (p=0.23). On day 14 after the virus inoculation, there were 2 eyes that developed retinitis out of 7 eyes with HDP-CDV, 5 eyes out of 5 eyes with CDV, and 5 eyes out of 5 eyes with dextrose (p=0.0062).

Conclusions: CDV can provide 5 weeks antiviral effect after intravitreal injection. However, HDP-CDV can provide at least 9 weeks antiviral effect following a single intravitreal injection of 42 µg.

Keywords: 503 drug toxicity/drug effects • 702 retinitis • 545 herpes simplex virus  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×